A citation-based method for searching scientific literature

Zhaowei Meng, Michiko Matsuse, Vladimir Saenko, Shunichi Yamashita, Peng Ren, Xiangqian Zheng, Qiang Jia, Jian Tan, Ning Li, Wei Zheng, Li Zhao, Norisato Mitsutake. IUBMB Life 2019
Times Cited: 5







List of co-cited articles
25 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Xue Yang, Jiao Li, Xiaoyi Li, Zhiyong Liang, Wen Gao, Jun Liang, Shujun Cheng, Yansong Lin. J Nucl Med 2017
43
80

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
370
80

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.
Rengyun Liu, Tao Zhang, Guangwu Zhu, Mingzhao Xing. Nat Commun 2018
83
80


2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
60

TERT promoter mutations in thyroid cancer.
Rengyun Liu, Mingzhao Xing. Endocr Relat Cancer 2016
183
60

Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
Johanna Wassermann, Marie-Odile Bernier, Jean-Philippe Spano, Charlotte Lepoutre-Lussey, Camille Buffet, Jean-Marc Simon, Fabrice Ménégaux, Frédérique Tissier, Monique Leban, Laurence Leenhardt. Oncologist 2016
24
40

Ultrasound characteristics of cervical lesions in patients with radioiodine refractory differentiated thyroid cancer: A strobe-compliant article.
Luying Gao, Yansong Lin, Yuxin Jiang, Hui Li, Qiong Gao, Xuehua Xi, Ying Wang, Xiao Yang, Xingjian Lai, Shenling Zhu,[...]. Medicine (Baltimore) 2019
3
66

NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features.
Catarina Tavares, Maria João Coelho, Catarina Eloy, Miguel Melo, Adriana Gaspar da Rocha, Ana Pestana, Rui Batista, Luciana Bueno Ferreira, Elisabete Rios, Samia Selmi-Ruby,[...]. Endocr Connect 2018
32
40

Predictive factors of outcome in poorly differentiated thyroid carcinomas.
Christelle de la Fouchardière, Myriam Decaussin-Petrucci, Julien Berthiller, Françoise Descotes, Jonathan Lopez, Jean-Christophe Lifante, Jean-Louis Peix, Anne-Laure Giraudet, Armelle Delahaye, Sandrine Masson,[...]. Eur J Cancer 2018
28
40

Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.
Zongjing Zhang, Dingxie Liu, Avaniyapuram Kannan Murugan, Zhimin Liu, Mingzhao Xing. Endocr Relat Cancer 2014
48
40

BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry.
Ana P Estrada-Flórez, Mabel E Bohórquez, Alejandro Vélez, Carlos S Duque, Jorge H Donado, Gilbert Mateus, Cesar Panqueba-Tarazona, Guadalupe Polanco-Echeverry, Ruta Sahasrabudhe, Magdalena Echeverry,[...]. Endocr Connect 2019
4
50

The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults.
Kepal N Patel, Linwah Yip, Carrie C Lubitz, Elizabeth G Grubbs, Barbra S Miller, Wen Shen, Peter Angelos, Herbert Chen, Gerard M Doherty, Thomas J Fahey,[...]. Ann Surg 2020
81
40

Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Young Shin Song, Jung Ah Lim, Hoonsung Choi, Jae-Kyung Won, Jae Hoon Moon, Sun Wook Cho, Kyu Eun Lee, Young Joo Park, Ka Hee Yi, Do Joon Park,[...]. Cancer 2016
91
40

Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis.
Huy Gia Vuong, Ahmed M A Altibi, Uyen N P Duong, Lewis Hassell. Clin Endocrinol (Oxf) 2017
50
40


TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.
Martyn Bullock, Yan Ren, Christine O'Neill, Anthony Gill, Adam Aniss, Mark Sywak, Stan Sidhu, Leigh Delbridge, Diana Learoyd, Florent de Vathaire,[...]. Clin Endocrinol (Oxf) 2016
37
40

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
390
40

Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
Rong Bu, Abdul K Siraj, Sasidharan Padmaja Divya, Yan Kong, Sandeep Kumar Parvathareddy, Maha Al-Rasheed, Khadija A S Al-Obaisi, Ingrid G Victoria, Saif S Al-Sobhi, Mohammed Al-Dawish,[...]. Int J Cancer 2018
33
40

Highly recurrent TERT promoter mutations in human melanoma.
Franklin W Huang, Eran Hodis, Mary Jue Xu, Gregory V Kryukov, Lynda Chin, Levi A Garraway. Science 2013
40


Frequency of TERT promoter mutations in human cancers.
João Vinagre, Ana Almeida, Helena Pópulo, Rui Batista, Joana Lyra, Vasco Pinto, Ricardo Coelho, Ricardo Celestino, Hugo Prazeres, Luis Lima,[...]. Nat Commun 2013
535
40

Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
Young Shin Song, Seong-Keun Yoo, Hwan Hee Kim, Gyeongseo Jung, Ah-Reum Oh, Ji-Young Cha, Su-Jin Kim, Sun Wook Cho, Kyu Eun Lee, Jeong-Sun Seo,[...]. Endocr Relat Cancer 2019
25
40


TERT promoter mutations in familial and sporadic melanoma.
Susanne Horn, Adina Figl, P Sivaramakrishna Rachakonda, Christine Fischer, Antje Sucker, Andreas Gast, Stephanie Kadel, Iris Moll, Eduardo Nagore, Kari Hemminki,[...]. Science 2013
40

Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer.
Zhong-Ling Qiu, Wei-Jun Wei, Zhen-Kui Sun, Chen-Tian Shen, Hong-Jun Song, Xin-Yun Zhang, Guo-Qiang Zhang, Xiao-Yue Chen, Quan-Yong Luo. Cell Physiol Biochem 2018
16
20

BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
André Uchimura Bastos, Gisele Oler, Bruno Heidi Nakano Nozima, Raquel Ajub Moysés, Janete Maria Cerutti. Eur J Endocrinol 2015
44
20


Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing.
Mingzhao Xing, Henning Usadel, Yoram Cohen, Yutaka Tokumaru, Zhongmin Guo, William B Westra, Betty C Tong, Giovanni Tallini, Robert Udelsman, Joseph A Califano,[...]. Cancer Res 2003
108
20

Comparison of 18F-AIF-NOTA-PRGD2 and 18F-FDG uptake in lymph node metastasis of differentiated thyroid cancer.
Weiwei Cheng, Zhenyu Wu, Sheng Liang, Hongliang Fu, Shuqi Wu, Yiyun Tang, Zhiyi Ye, Hui Wang. PLoS One 2014
12
20

Is malignant nodule topography an additional risk factor for metastatic disease in low-risk differentiated thyroid cancer?
Alfredo Campennì, Luca Giovanella, Massimiliano Siracusa, Maria Elena Stipo, Angela Alibrandi, Mariapaola Cucinotta, Rosaria M Ruggeri, Sergio Baldari. Thyroid 2014
18
20

Thyroid cancer dosimetry using clearance fitting.
E E Furhang, S M Larson, P Buranapong, J L Humm. J Nucl Med 1999
43
20


miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.
Chen-Tian Shen, Zhong-Ling Qiu, Hong-Jun Song, Wei-Jun Wei, Quan-Yong Luo. J Exp Clin Cancer Res 2016
25
20



PTEN-knockdown disrupts the morphology, growth pattern and function of Nthy-Ori 3-1 cells by downregulating PAX8 expression.
Zhuo Sun, Jinqi Lu, Muyu Wu, Changli Ouyang, Yueping Xing, Xiancun Hou, Zhenduo Shi, Yongping Wu. Oncol Lett 2019
1
100

Thyroid-Specific Genes Expression Uncovered Age-Related Differences in Pediatric Thyroid Carcinomas.
Maria Isabel Cunha Vieira Cordioli, Lais Moraes, Maria Teresa de Seixas Alves, Rosana Delcelo, Osmar Monte, Carlos Alberto Longui, Adriano Namo Cury, Janete Maria Cerutti. Int J Endocrinol 2016
15
20

Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression.
Luchuan Li, Bin Lv, Bo Chen, Ming Guan, Yongfeng Sun, Haipeng Li, Binbin Zhang, Changyuan Ding, Shan He, Qingdong Zeng. Biochem Biophys Res Commun 2015
32
20

FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake.
Florian C Gaertner, Shozo Okamoto, Tohru Shiga, Yoichi M Ito, Yuko Uchiyama, Osamu Manabe, Naoya Hattori, Nagara Tamaki. Clin Nucl Med 2015
8
20


The rs2910164 Genetic Variant of miR-146a-3p Is Associated with Increased Overall Mortality in Patients with Follicular Variant Papillary Thyroid Carcinoma.
Marta Kotlarek, Anna Kubiak, Małgorzata Czetwertyńska, Michał Świerniak, Wojciech Gierlikowski, Monika Kolanowska, Elwira Bakuła-Zalewska, Sissy M Jhiang, Krystian Jażdżewski, Anna Wójcicka. Int J Mol Sci 2018
11
20

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
20

Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
Koichiro Abe, Umiko Ishizaki, Toshihiro Ono, Kiyomi Horiuchi, Kazuko Kanaya, Shuji Sakai, Takahiro Okamoto. Ann Nucl Med 2020
3
33

Tc-99m imaging in thyroidectomized differentiated thyroid cancer patients immediately before I-131 treatment.
Chi-Jung Tsai, Cheng-Yi Cheng, Daniel Hueng-Yuan Shen, Shou Jen Kuo, Lien-Yen Wang, Chiang-Hsuan Lee, Jhi-Joung Wang, Ming-Che Chang, Wen-Sheng Huang. Nucl Med Commun 2016
6
20

Assessment of Minimum 124I Activity Required in Uptake Measurements Before Radioiodine Therapy for Benign Thyroid Diseases.
Anja S Gabler, Christian Kühnel, Thomas Winkens, Martin Freesmeyer. J Nucl Med 2016
6
20

Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?
Gauri R Khorjekar, Douglas Van Nostrand, Carlos Garcia, Jeffrey O'Neil, Shari Moreau, Francis B Atkins, Mihriye Mete, Michael H Orquiza, Kenneth Burman, Leonard Wartofsky. Thyroid 2014
24
20


Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.
Ricardo Costa, Benedito A Carneiro, Sunandana Chandra, Sachin G Pai, Young Kwang Chae, Jason B Kaplan, Hannah B Garrett, Mark Agulnik, Peter A Kopp, Francis J Giles. Drug Des Devel Ther 2016
24
20

Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer.
Domenico Albano, Maria Beatrice Panarotto, Rexhep Durmo, Carlo Rodella, Francesco Bertagna, Raffaele Giubbini. Endocrine 2019
19
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.